How can subcellular compartmentalization defects be measured as biomarkers in living neurons?

neuroscience partially_addressed
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
—
Novelty
—
Mechanistic
—
Druggability
—
Priority
90%
Importance
—
Tractability
—
Market price
50%

Description

The clinical trialist identified this as a ‘fatal clinical flaw’ - no validated biomarkers exist to measure restored compartmentalization in patients. Without measurable endpoints, therapeutic approaches targeting subcellular localization cannot advance to clinical trials.

Source: Debate session sess_SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47 (Analysis: SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47)

Resolution criteria

Resolution requires: (1) validated biomarker panel (≥3 markers) measured in CSF or blood from AD patients (n≥100) that correlates with compartmentalization defects in iPSC-derived neurons; (2) cross-sectional study showing biomarker levels change with disease severity (Braak stage); (3) longitudinal validation showing biomarker predicts therapeutic response in a clinical trial (Phase II or higher). Biomarkers must have AUC ≥0.80 for distinguishing patients from age-matched controls. Single-marker studies are insufficient.